Invivyd (IVVD) Is Up 26.8% After FDA Clears Phase 3 Trials for COVID Antibody Candidate

• Invivyd, Inc. recently announced that the FDA has cleared its Investigational New Drug application and provided feedback to advance the REVOLUTION program, enabling pivotal Phase 3 trials of its COVID prevention antibody candidate VYD2311.
• This milestone positions Invivyd to potentially offer a non-vaccine monoclonal antibody alternative for COVID prevention, targeting populations seeking medical-grade protection beyond traditional vaccines.
• We'll now examine how FDA clearance to start Phase 3 trials for VYD2311 may affect Invivyd's investment narrative and pipeline outlook.

We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Invivyd Investment Narrative Recap

To be a shareholder in Invivyd right now, you need confidence in the company’s ability to launch monoclonal antibodies as key COVID-19 prevention tools, despite continuing regulatory and competitive pressures. The FDA clearance to move VYD2311 into pivotal Phase 3 trials addresses a critical near-term catalyst for the business, but the most significant risk, reliance on a limited COVID-focused product portfolio, remains largely unchanged for now.

The company’s recent $350 million shelf registration stands out, putting Invivyd in a stronger position to fund the major clinical milestones tied to the REVOLUTION program. Whether this financial flexibility can neutralize pipeline and execution risks will likely depend on the success of the upcoming pivotal trials and ongoing demand for COVID-19 preventatives.

By contrast, investors should also be aware that even with regulatory progress, questions remain about the speed and success of broader product diversification strategies if...

Read the full narrative on Invivyd (it's free!)

Invivyd's narrative projects $349.7 million revenue and $100.0 million earnings by 2028. This requires 96.3% yearly revenue growth and a $210.1 million increase in earnings from -$110.1 million today.

Uncover how Invivyd's forecasts yield a $3.00 fair value, a 111% upside to its current price.

Exploring Other Perspectives

Fifteen members of the Simply Wall St Community see Invivyd’s fair value ranging from US$1.00 to US$17.05, showing wide-ranging expectations. With Phase 3 trial approval in focus, attention is turning to pipeline concentration risk as a key issue impacting future performance.

Explore 15 other fair value estimates on Invivyd - why the stock might be worth 30% less than the current price!

Build Your Own Invivyd Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Invivyd research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Invivyd research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Invivyd's overall financial health at a glance.

Looking For Alternative Opportunities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com